Pharmacological characterization of a novel, potent, selective, and orally active fatty acid amide hydrolase inhibitor, PKM‐833 [(R)‐N‐(pyridazin‐3‐yl)‐4‐(7‐(trifluoromethyl)chroman‐4‐yl)piperazine‐1‐carboxamide] in rats: Potential for the treatment of inflammatory pain

Recently, we identified a novel fatty acid amide hydrolase (FAAH) inhibitor, PKM‐833 [(R)‐N‐(pyridazin‐3‐yl)‐4‐(7‐(trifluoromethyl)chroman‐4‐yl)piperazine‐1‐carboxamide]. The aim of the present study is to characterize the pharmacological profile of PKM‐833 in vitro and in vivo. PKM‐833 showed poten...

Descripción completa

Detalles Bibliográficos
Autores principales: Endo, Toshiya, Takeuchi, Takashi, Maehara, Shunsuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043261/
https://www.ncbi.nlm.nih.gov/pubmed/32101384
http://dx.doi.org/10.1002/prp2.569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043261/
https://www.ncbi.nlm.nih.gov/pubmed/32101384
http://dx.doi.org/10.1002/prp2.569

Ejemplares similares